Adelaide Research & Scholarship: Search

Search

Results 1-10 of 34 (Search time: 0.008 seconds).

previous
1
2
3
4
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2001	Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer	Han, G.; Foster, B.; Mistry, S.; Buchanan, G.; Harris, J.; Tilley, W.; Greenberg, N.
	2001	Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function	Buchanan, G.; Yang, M.; Harris, J.; Nahm, H.; Han, G.; Moore, N.; Bentel, J.; Matusik, R.; Horsfall, D.; Marshall, V.; Greenberg, N.; Tilley, W.
	2006	Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant	Butler, L.; Centenera, M.; Neufing, P.; Buchanan, G.; Choong, C.; Ricciardelli, C.; Saint, K.; Lee, M.; Ochnik, A.; Yang, M.; Brown, M.; Tilley, W.
	2001	Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase	Butler, L.; Webb, Y.; Agus, D.; Higgins, B.; Tolentino, T.; Kutko, M.; LaQuaglia, M.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H.; Breslow, R.; Richon, V.; Rifkind, R.; Marks, P.
	2001	Collocation of androgen receptor gene mutations in prostate cancer	Buchanan, G.; Greenberg, N.; Scher, H.; Harris, J.; Marshall, V.; Tilley, W.
	2007	Androgen receptor coregulators and their involvement in the development and progression of prostate cancer	Chmelar, R.; Buchanan, G.; Need, E.; Tilley, W.; Greenberg, N.
	2020	Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion	Kohno, S.; Linn, P.; Nagatani, N.; Watanabe, Y.; Kumar, S.; Soga, T.; Takahashi, C.
	2019	Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer	Watt, M.J.; Clark, A.K.; Selth, L.A.; Haynes, V.R.; Lister, N.; Rebello, R.; Porter, L.H.; Niranjan, B.; Whitby, S.T.; Lo, J.; Huang, C.; Schittenhelm, R.B.; Anderson, K.E.; Furic, L.; Wijayaratne, P.R.; Matzaris, M.; Montgomery, M.K.; Papargiris, M.; Norden, S.; Febbraio, M.; et al.
	2017	Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer	Paltoglou, S.; Das, R.; Townley, S.; Hickey, T.; Tarulli, G.; Coutinho, I.; Fernandes, R.; Hanson, A.; Denis, I.; Carroll, J.; Dehm, S.; Raj, G.; Plymate, S.; Tilley, W.; Selth, L.
	2021	ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer	Centenera, M.M.; Scott, J.S.; Machiels, J.; Nassar, Z.D.; Miller, D.C.; Zinonos, I.; Dehairs, J.; Burvenich, I.J.G.; Zadra, G.; Chetta, P.; Bango, C.; Evergren, E.; Ryan, N.K.; Gillis, J.L.; Mah, C.Y.; Tieu, T.; Hanson, A.R.; Carelli, R.; Bloch, K.; Panagopoulos, V.; et al.